Affibody
Founded Year
1998Stage
Other Investors | AliveAbout Affibody
Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing biotherapeutics based on its unique proprietary technology platforms: Affibody molecules and Albumod. The company is based in Solna, Sweden.
Affibody Headquarter Location
Voltavagen 13
161 02,
Sweden
Affibody Patents
Affibody has filed 49 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immunology
- Proteins
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
10/28/2016 | 10/26/2021 | Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Monoclonal antibodies for tumors | Grant |
Application Date | 10/28/2016 |
---|---|
Grant Date | 10/26/2021 |
Title | |
Related Topics | Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Monoclonal antibodies for tumors |
Status | Grant |
Latest Affibody News
Jun 7, 2022
Affibody AB and its development partners, Acelyrin Inc. and Inmagene Biopharmaceuticals Co. Ltd., are accelerating plans to move izokibep into phase III studies in psoriatic arthritis following better-than-expected phase II efficacy combined with an apparently clean safety profile.
When was Affibody founded?
Affibody was founded in 1998.
What is Affibody's latest funding round?
Affibody's latest funding round is Other Investors.
Who are the investors of Affibody?
Investors of Affibody include Life Equity Sweden, Permira, AP Fonden 3, GZ Group, SV Health Investors and 5 more.
Who are Affibody's competitors?
Competitors of Affibody include Elusys Therapeutics, Acumen Pharmaceuticals, Athersys, Elcelyx Therapeutics, Arcion Therapeutics and 13 more.
You May Also Like
AutekBio is a biotech firm headquartered in the Bay Area, US.
ugichem is developing antisense drugs based on its proprietary Ugimer platform for unmet medical needs in immune-mediated inflammatory diseases (IMID). Ugimers overcome the shortcomings of standard antisense technologies or RNAi. In contrast, Ugimers are not derived from natural nucleic acids but are based on the peptide nucleic acid (PNA) backbone and carry specific side chains for improved delivery, efficacy and specificity. This innovative design provides Ugimers with unique biopharmaceutical properties allowing them access to previously inaccessible organs, cells and cellular compartments, including the immune system. Moreover, Ugimers are the first and only antisense drugs that have efficacy in mitochondria.
Elara Pharmaceuticals is a Heidelberg, Germany-based biotech company focused on the development of drugs for the treatment of different cancers.
Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease. ST101, the company's lead compound, represents an agent that, in animal models, has demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. ST101 has completed Phase I studies in both healthy volunteers and AD patients. It is being evaluated in Phase II Proof-of-Concept trials.
Nano Carrier is a biotech company using nanotechnology to improve patient Quality of Life with a focus on cancer.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.